DrugPatentWatch Database Preview

Details for Patent: 10,231,965

« Back to Dashboard

Which drugs does patent 10,231,965 protect, and when does it expire?

Patent 10,231,965 protects ROZLYTREK and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 10,231,965

Title:	Molecules for administration to ROS1 mutant cancer cells
Abstract:	Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Lim; Jonathan (San Diego, CA), Ardini; Elena (Sesto San Giovanni, IT), Menichincheri; Maria (Milan, IT)
Assignee:	IGNYTA, INC. (San Diego, CA) NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano, IT)
Application Number:	14/623,904
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,231,965

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No						TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No						TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-002	Aug 15, 2019		RX	Yes	Yes						TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION

International Family Members for US Patent 10,231,965

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015220832
Canada	2933623
Chile	2016001507